REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET.
The live webcast will be accessible under Events and Presentations in the Investors section of the company’s website. This archived webcast will be available on the Adverum website following the presentation for 30 days.
About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
CONTACT: Investor Relations Contact Myesha Lacy Vice President, Investor Relations and Corporate Communications Adverum Biotechnologies, Inc. T: 650-649-1257 E: mlacy@adverum.com Media Contact Andrea Cohen Sam Brown Inc. T: 917-209-7163 E: andreacohen@sambrown.com
TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- Happy Panda announces its official market launch with a…
GARDENA, Calif., Feb. 2, 2026 /PRNewswire/ -- FUGO Precision 3D, developer of the world's first all-in-one…
OXNARD, CA / ACCESS Newswire / February 2, 2026 / Quality Dental Services functions as…
Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…
BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…
New online network makes it simple, affordable and stigma-free to connect with licensed therapistsDETROIT, Feb.…